A healthcare investment firm with offices in USA actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. The firm makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.
The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.
The firm invests primarily in private companies but will also consider private investment in public equity opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply